News >

Retrospective Results Show High pCR With Dose-Dense Regimen in HER2+ Breast Cancer

Ellie Leick
Published: Friday, Feb 14, 2020

Jasmeet C. Singh, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

Jasmeet C. Singh, MD

Neoadjuvant dose-dense doxorubicin and cyclophosphamide plus paclitaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta; ACTHP) led to encouraging pathologic complete response (pCR) rates in patients with HER2-positive breast cancer, according to results of a retrospective analysis.

We have already come a long way in our HER2-positive populations, but there is always room for improvement. There might be some interest in looking at novel combinations of these dual HER2-targeted therapies with immunotherapy to further improve pCR rates and overall response. We have some exciting pCR data in triple-negative disease, which shows that immunotherapy really adds to improvement in pCR rates. In a totally different scenario, it may be useful to see if we can avoid surgery in patients who have excellent responses. This is a question of the future.
Singh JC, Patil S, Norton L, et al. Disease free survival rate with dose dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: a single institution experience. Presented at: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX. Abstract P2-16-10.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication